Alfred Gilman has been named chief scientific officer of the Cancer Prevention and Research Institution of Texas.
As CSO, Gilman will spearhead CPRIT's research division, and will be responsible for overseeing recruiting and peer-review panels; developing and implementing intellectual property agreements; and overseeing and monitoring research grants.
Gilman will retire from his position as executive vice president for academic affairs and provost of the University of Texas Southwestern Medical Center and dean of the University of Texas Southwestern Medical School to join CPRIT. He will hold the honorary title of emeritus professor of pharmacology from UT Southwestern.
Gilman has also served as chairman of the department of pharmacology at UT Southwestern Medical School. Prior to this he was a faculty member in the department of pharmacology at the University of Virginia in Charlottesville. He completed his postdoc in biochemical genetics at the National Institutes of Health, and earned his MD and PhD in pharmacology from Case Western Reserve University.
In 1994, Gilman received the Nobel Prize in Physiology or Medicine for discovering G proteins and their role in cellular signal transduction.
UNeMed, the for-profit technology-transfer arm for the University of Nebraska Medical Center, said that Michael Dixon will be named its president as of May 1.
James Linder, current president and CEO of UNeMed, will remain as CEO.
Dixon is currently director of the UNMC intellectual property office, and vice president and COO of UNeMed, positions he has held since 2006 when the IP office and UNeMed merged. Prior to this he was the faculty liaison/technology transfer associate in the UN IPO.
He received a PhD in molecular biology from the UNMC Eppley Cancer Center in 2003.